Hematologic Oncology

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Patients with newly diagnosed mantle cell lymphoma assigned to frontline chemotherapy had a survival advantage when they were able to receiver higher dose intensities of bortezomib (Velcade).

Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

James F. Holland, MD, reminisces on nearly 70 years of practicing medicine.

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

The FDA has approved CPX-351 for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD.

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

The FDA has approved enasidenib along with a companion diagnostic as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia.

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Kendra Sweet, MD, discusses the various factors that must be taken into account when prescribing first-line therapies to patients with CML, novel studies, and TKI discontinuation.

Venetoclax has received an FDA breakthrough therapy designation for use in combination with low dose cytarabine in treatment-naïve elderly patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Rami Komrokji, MD, shares his insight on the various types of MPNs, how these diseases can be diagnosed and managed, and the next steps needed to improve patient outcomes.

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Mohamed Kharfan-Dabaja, MD, discusses the future of PNH treatment, the various symptoms that can present in PNH, and the challenges that still remain for further improving outcomes.

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of midostaurin to treat adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive.

Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA’s Oncologic Drugs Advisory Committee voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).